AVTR: Avantor, Inc. Stock

by  •  • Comments Off on AVTR: Avantor, Inc. Stock

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M) 15,500.86
Enterprise Value ($M) 20,588.96
Book Value ($M) 5,336.30
Book Value / Share 7.86
Price / Book 2.90
NCAV ($M) -5,106.00
NCAV / Share -7.52
Price / NCAV -3.04

Profitability (mra)
Return on Invested Capital (ROIC) 0.02
Return on Assets (ROA) 0.02
Return on Equity (ROE) 0.05

Liquidity (mrq)
Quick Ratio 1.05
Current Ratio 1.61

Balance Sheet (mrq) ($M)
Current Assets 2,321.10
Assets 12,763.40
Liabilities 7,427.10
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 6,967.20
Operating Income 857.20
Net Income 321.10
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 870.00
Cash from Investing -143.70
Cash from Financing -843.70

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
07-10 13G/A T. Rowe Price Investment Management, Inc. 10.30 32.31
02-16 13G/A Price T Rowe Associates Inc /md/ 2.90 0.00
02-13 13G/A Vanguard Group Inc 9.66 5.81
02-13 13G Dodge & Cox 9.00
02-12 13G/A BlackRock Inc. 6.80 16.48

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-07-26 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-04-26 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-10-27 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-07-28 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-26 3,233,620 19,139,665 16.89
2024-07-25 5,768,228 34,964,073 16.50
2024-07-24 4,341,249 25,760,132 16.85
2024-07-23 3,395,754 11,393,913 29.80
2024-07-22 917,535 4,855,347 18.90

(click for more detail)

Similar Companies
A – Agilent Technologies, Inc. AME – AMETEK, Inc.
BIO – Bio-Rad Laboratories, Inc. BIO.B – Bio-Rad Laboratories, Inc.


Financial data and stock pages provided by
Fintel.io